share_log

Earnings Call Summary | Asensus Surgical(ASXC.US) Q1 2024 Earnings Conference

Earnings Call Summary | Asensus Surgical(ASXC.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Asensus Surgical (ASXC.US) 2024 年第一季度業績會議
富途資訊 ·  05/15 11:59  · 電話會議

The following is a summary of the Asensus Surgical, Inc. (ASXC) Q1 2024 Earnings Call Transcript:

以下是Asensus Surgical, Inc.(ASXC)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Asensus Surgical's Q1 2024 revenue was $1.1 million, seeing a slight increase from Q1 2023's $1 million. This consists of $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.3 million in services.

  • The company saw an increase in total operating expenses to $22.7 million from $20.4 million last year.

  • The net loss was $22.5 million, equating to $0.08 per share, in comparison to Q1 2023's net loss of $22.2 million, or $0.09 per share.

  • The company reported approximately $8 million in cash, cash equivalents, and short-term investments by the end of March 2024.

  • Asensus Surgical的2024年第一季度收入爲110萬美元,較2023年第一季度的100萬美元略有增加。這包括50萬美元的租賃收入、30萬美元的儀器和配件以及30萬美元的服務。

  • 該公司的總運營支出從去年的2,040萬美元增加到2,270萬美元。

  • 淨虧損爲2,250萬美元,相當於每股虧損0.08美元,而2023年第一季度的淨虧損爲2,220萬美元,合每股虧損0.09美元。

  • 截至2024年3月底,該公司報告了約800萬澳元的現金、現金等價物和短期投資。

Business Progress:

業務進展:

  • Negotiations for Asensus Surgical's potential acquisition by KARL STORZ are ongoing, with a proposed acquisition deal for all outstanding common stock at $0.35 per share in cash.

  • The Senhance system was utilised in approximately 900 procedures worldwide in Q1 2024, with an expected increase in pediatric procedures, largely due to the system's advantageous design.

  • An additional institution within one of Japan's largest private hospital systems has agreed to lease and utilize a Senhance Surgical System, as part of Asensus Surgical's market expansion.

  • The company is keen on advancing the development of the next-generation LUNA Surgical System and its digital solutions, while also driving the adoption of the current Senhance platform.

  • 關於KARL STORZ可能收購Asensus Surgical的談判仍在進行中,擬議以每股0.35美元的現金收購所有已發行普通股。

  • 2024年第一季度,Senhance系統在全球約900例手術中使用,預計兒科手術數量將增加,這主要歸功於該系統的優勢設計。

  • 作爲Asensus Surgical市場擴張的一部分,日本最大的私立醫院系統之一中的另一家機構已同意租賃和使用Senhance手術系統。

  • 該公司熱衷於推進下一代LUNA手術系統及其數字解決方案的開發,同時推動當前Senhance平台的採用。

More details: Asensus Surgical IR

更多詳情: Asensus 外科紅外

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論